Identification and assessment of PLK1/2/3/4 in lung adenocarcinoma and lung squamous cell carcinoma: Evidence from methylation profile. [PDF]
Deng S+5 more
europepmc +1 more source
Delivery of A Chemically Modified Noncoding RNA Domain Improves Dystrophic Myotube Function
CYTOR is a pro‐myogenic ncRNA in skeletal muscle. Here, chemical probing of CYTOR, coupled with functional cellular assays identifies exon 2 as an independent myogenic RNA domain. Chemical engineering of CYTOR exon 2 RNA improves pharmacologic properties, including RNA stability and cell‐autonomous immunogenicity.
Zeinabou Niasse‐Sy+6 more
wiley +1 more source
Differences between lung adenocarcinoma and lung squamous cell carcinoma: Driver genes, therapeutic targets, and clinical efficacy. [PDF]
Shen Y, Chen JQ, Li XP.
europepmc +1 more source
TTN/TP53 mutation might act as the predictor for chemotherapy response in lung adenocarcinoma and lung squamous carcinoma patients. [PDF]
Xue D+5 more
europepmc +1 more source
A Case of Intradural Extramedullary Cord Tumor Metastasis from Adenocarcinoma of the Lung [PDF]
Je Kyung Lee+2 more
openalex +1 more source
Schematic diagram of the working model of TRAF3IP3 in the coordination of ER stress and autophagy related apoptosis in lung cancer cells. Abstract TNF receptor‐associated factor 3 interacting protein 3 (TRAF3IP3/T3JAM) exhibits dual roles in cancer progression. While upregulated in most malignancies and critical for immune regulation.
Guang Zhao+11 more
wiley +1 more source
Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung. [PDF]
Miao H+6 more
europepmc +1 more source
Different Subtypes of Human Lung Adenocarcinoma Caused by Different Etiological Factors [PDF]
Takehisa Hashimoto+9 more
openalex +1 more source
αPD‐1 therapy has left an indelible mark in the field of NSCLC treatment; however, its efficacy is limited in clinical practice owing to the effector T‐cell exhaustion. These findings underscore CK2B as a promising target for overcoming the exhaustion of effector CD8+ T cells, thereby enhancing the efficacy of αPD‐1 and adoptive cell therapies in NSCLC.
Shaochuan Liu+15 more
wiley +1 more source